A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia

NCT01529424 Phase 2 COMPLETED

The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.

Details

Lead sponsor	Ionis Pharmaceuticals, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	89
Start date	2012-02
Completion	2014-01

Conditions

• Hypertriglyceridemia

Interventions

• ISIS apoC-III Rx
• ISIS apoC-III Rx
• ISIS apoC-III Rx
• Placebo
• Placebo
• Placebo

Primary outcomes

• VLDL apoC-III — 92 Days
  The effect of treatment with ISIS ApoC-III Rx or Placebo on fasting total apoC-III levels.

Countries

United States, Canada